RINVOQ

Product Overview

About RINVOQ

RINVOQ is a prescription medication containing the active ingredient upadacitinib, a Janus kinase (JAK) inhibitor. It is used to treat moderate to severe active rheumatoid arthritis (RA) in adults who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs), and to treat active psoriatic arthritis (PsA) in adults who have had an inadequate response or intolerance to one or more DMARDs.

Key Benefits & Uses

• Treatment of moderate to severe active rheumatoid arthritis (RA) in adults who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs)
• Treatment of active psoriatic arthritis (PsA) in adults who have had an inadequate response or intolerance to one or more DMARDs

Active Ingredient & Action

Upadacitinib works by blocking the action of Janus kinases (JAKs), enzymes that play a role in the inflammatory response. By inhibiting these enzymes, upadacitinib reduces inflammation and slows disease progression in patients with RA and PsA.

Important Notes

RINVOQ is available in tablet form and should be taken orally once daily. It is essential to follow the prescribed dosage and schedule to achieve optimal results. Patients should also inform their healthcare provider about any medical conditions, medications, or supplements they are taking before starting treatment with RINVOQ. Common side effects may include headache, nausea, and fatigue. Patients should consult their healthcare provider if they experience any adverse reactions or have concerns about their treatment.